Skip to content

Incidence of Macular Edema in a Uveitis Population

Incidence of Macular Edema in a Uveitis Population of 1500 Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06686641
Enrollment
1550
Registered
2024-11-13
Start date
2024-05-01
Completion date
2025-02-01
Last updated
2024-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular Edema, Non-infectious Uveitis

Keywords

Epidemiology of uveitis, Incidence of macular edema in a uveitis population, Management of macular edema secondary to uveitis, Uveitis, Macular Edema, Non infectious uveitis, Non-infectious uveitis

Brief summary

Macular edema from uveitis is a serious condition that can lead to vision loss. Uveitis is an inflammation inside the eye, and macular edema is when fluid builds up in the central part of the retina, called the macula, which is crucial for clear vision. This fluid buildup can blur vision, sometimes severely. Managing this condition can be challenging and may require several treatments to reduce the fluid and protect sight. While we know macular edema is a common cause of vision loss in uveitis, there's limited data on how often it affects people in Europe

Interventions

DRUGLocal and systemical treatment

Evaluating the management of the edema including topical/local treatment (dexamethasone and NSAID, periocular injections, and dexamethasone intravitreal implant) and systemic treatment (prednisolone, DMARD, and biological agents, for example TNF-alpha inhibitors and interleukin-6 inhibitors). Moreover, the duration of any treatment as well as numbers of injections or implants.

Sponsors

Aalborg University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Hospital-admitted patients in the North Denmark Region with non-infectious uveitis. * Both juvenile and adult patients. * Diagnosed with non-infectious uveitis by a medical doctor. * Patients presenting with unspecific macular edema may be included if medical records indicate uveitis as the cause of the edema.

Exclusion criteria

* Patients incorrectly classified as having uveitis based on their medical records (no confirmed diagnosis of uveitis). * Patients with infectious uveitis. * Macular edema due to other cause than uveitis will not count as uveitis associated edema

Design outcomes

Primary

MeasureTime frameDescription
Incidence of Macular Edema in patients with Uveitis10 yearsThe outcome of interest is macular edema in non-infectious uveitis. We will estimate the incidence rate and cumulative incidence of macular edema in patients with uveitis. In addition, the population will be stratified according to sex, age, non-infectious uveitis subtype, HLA- subtype, and ethnicity (if available), and the rate and risk of macular edema will be assessed for each strata. The incidence rate for macular edema will be calculated for a 1-10 years follow-up periods. Furthermore, the cumulative incidence will be assessed using the Aalen Johansen estimator. The stratified groups will be compared using a cox proportional hazard model to quantify the differences between the respective groups. Patients will be excluded if essential information is missing in their medical journal. Follow-up will terminate in case the patient moves to an address outside the North Denmark Region.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026